Aquestive Therapeutics AQST 深 沪
已收盘 07-18 16:00:00 美东时间
4.20
-0.170
-3.89%
华盛通- 最 高4.50
- 今 开4.445
- 成交量 251.30万股
- 最 低 4.20
- 昨 收 4.37
- 总市值 4.17亿
- 52周最高 5.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.12
- 委 比 57.25%
- 总股本 9932.79万
- 历史最高 20.696
- 量 比 2.03
- 振 幅 6.86%
- 历史最低 0.618
- 每 手 1
- 风险率 0.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aquestive Seeks Approval for Needle-Free Allergy Film in Canada and Europe, Eyes Global Expansion
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery
07-15 19:05
Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film
Aquestive Therapeutics announced plans for a meeting with Health Canada in the third quarter of 2025 to discuss their New Drug Submission for Anaphylm™ (epinephrine) Sublingual Film and submitted an initial briefing book to the European Medicines Agency. CEO Dan Barber emphasized these steps as key to their ex-U.S. regulatory strategy, aiming to bring needle-free Anaphylm to underserved patients globally. Anaphylm, designed to be orally administe...
07-15 11:00
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics announced that its management team will participate in the Leerink Partners Therapeutics Forum on July 9, 2025, focusing on immunology, inflammation, and metabolism. The company, which develops innovative oral and topical treatments, is advancing a severe allergic reaction therapy and a topical gel for dermatological conditions. The event will also include one-on-one investor meetings.
07-07 11:00
Aquestive Highlights Oral Epinephrine Film for Severe Allergies at Upcoming Chicago Summit
Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery
06-25 19:01
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit
Aquestive Therapeutics will present two posters on Anaphylm™ at the CFAAR Food Allergy Summit, highlighting its stability under extreme conditions and rapid pharmacokinetic responses. Anaphylm is an orally administered epinephrine film aimed to treat severe allergic reactions and anaphylaxis. If approved by the FDA, it would be the first oral epinephrine option in the U.S. The company emphasizes its convenience, portability, and weather-resistanc...
06-25 11:00
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Aquestive gains as allergy therapy undergoes FDA review
Aquestive Therapeutics (NASDAQ:AQST) added ~5% in the premarket on Monday after the biopharma announced that the FDA accepted its New Drug Application for allergy therapy Anaphylm for review. With the...
06-16 20:23
The FDA Has Accepts Aquestive Therapeutics' New Drug Application For Anaphylm For Type 1 Allergic Reactions, Including Anaphylaxis, With PDUFA Target Action Date Of January 31, 2026
If approved by the FDA, Anaphylm would be the first and only orally delivered epinephrine option for the treatment of severe allergic reactions in the United States.
06-16 19:04
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions
The U.S. Food and Drug Administration (FDA) has accepted Aquestive Therapeutics' New Drug Application (NDA) for Anaphylm™, an orally delivered epinephrine treatment for Type 1 allergic reactions, including anaphylaxis, with a target action date of January 31, 2026. Anaphylm, designed to be a device-free, sublingual film, aims to address accessibility and administration fears associated with traditional epinephrine devices. FDA has also indicated ...
06-16 11:00
美股大行评级 | 潜在涨幅417.8%！RBC Capital上调Perspective Therapeutics目标价至16美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136940401951563776.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Perspective Therapeutics(CATX)"跑赢大市"评级，目标价从15美元升至16美元</p> <p>• Canaccord Genuity：维持Taysha Gene Th
06-04 08:35
